SLC16A3 as a novel therapeutic target for overcoming radioresistance and chemoresistance in lung cancer
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2025.153204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Hye Min Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, 46033, Republic of Korea; Department of Biological Scienc…. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Radiation Tolerance, Monocarboxylic Acid Transporters. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Radiotherapy and chemotherapy are central components of lung cancer treatment. However, the development of therapeutic resistance significantly limits their efficacy. Here, we identified SLC16A3 as a potential biomarker associated with radioresistance and chemoresistance in lung cancer. Transcriptomic and protein analyses revealed significantly higher SLC16A3 expression in radioresistant R-H460 cells than in parental H460 cells, and immunohistochemistry further confirmed higher SLC16A3 expression in human lung tumors than in healthy tissues. Silencing SLC16A3 significantly reduced cell survival and promoted caspase-3-dependent apoptosis, which was further enhanced by ionizing radiation or cisplatin treatment. Phospho-kinase array profiling demonstrated activation of the p38-MAPK pathway upon SLC16A3 inhibition, and pharmacological blockade of p38 (SB203580) attenuated apoptosis, confirming that SLC16A3 knockdown-induced apoptosis is p38-dependent. Collectively, these findings uncover a previously unrecognized SLC16A3-p38-caspase signaling axis that promotes therapeutic resistance and highlight SLC16A3 as a promising therapeutic target for overcoming radioresistance and chemoresistance in lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, 46033, Republic of Korea; Department of Biological Science, Inje University, Gimhae, 50834, Republic of Korea.
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, 46033, Republic of Korea.
- Department of Biological Science, Inje University, Gimhae, 50834, Republic of Korea; Department of Digital Anti-Aging Healthcare, Inje University, Gimhae, 50834, Republic of Korea.
- Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, 01812, Republic of Korea.
- Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, 46033, Republic of Korea. Electronic address: jihan918@dirams.re.kr.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
Zitieren
APA
Kim, H. M., Bae, M. J., Lee, C. G., Jo, W. S., Kye, Y. U., Kim, H., Kang, Y. R., Han, S. J., Hwang, S. G., & Baek, J. H. (2026). SLC16A3 as a novel therapeutic target for overcoming radioresistance and chemoresistance in lung cancer. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.153204
Vancouver
Kim HM, Bae MJ, Lee CG, Jo WS, Kye YU, Kim H, et al. SLC16A3 as a novel therapeutic target for overcoming radioresistance and chemoresistance in lung cancer. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2025.153204
BibTeX
@article{Kim2026,
author = {Kim, Hye Min and Bae, Min Ji and Lee, Chang Geun and Jo, Wol Soon and Kye, Yong Uk and Kim, HyoJin and Kang, Yeong-Rok and Han, Seung Jin and Hwang, Sang-Gu and Baek, Jeong-Hwa},
title = {SLC16A3 as a novel therapeutic target for overcoming radioresistance and chemoresistance in lung cancer},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2025.153204}
}
EUVIMED